drugset / Trial / NCT04235868

Mesenchymal Stem Cell-derived Pleiotropic Factor in Treating Non-healing Wounds

NCT04235868 ↗

Phase 1 Unknown 30 enrolled Chinese PLA General Hospital
RandomizedParallel-groupDouble-blindTreatment

Summary

Chronic wounds do not heal for prolonged periods of time with the significant financial burden on the healthcare system. It has become increasingly essential to improve our clinical treatments. The most promising potential treatment options rely on stem cell-based therapies. A large body of evidence indicates that mesenchymal stem cells can promote wound closure of chronic wounds in animal models and in preclinical studies. MSCs efficacy depends mostly on their paracrine activity. All the bioactive factors and cytokines in MSCs secretions constitute can be collected in the conditioned medium. In here, stem cell-derived conditioned medium was further made into a lyophilized powder. Patients with chronic wounds were enrolled. The wounds in control group treated with fibroblast growth factor commonly used in clinical practice. The wounds in experimental group treated with lyophilized powder. The effectiveness and safety of lyophilized powder will evaluate for chronic wounds.

Timeline

Start
2019-10-20
Primary completion
2020-08-30
Completion
2020-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Stem cell-derived derived pleiotropic factor Unknown — Topical
Comparator fibroblast growth factor Protein / enzyme biologic — Topical

Indications

No indication recorded.